Stay updated with breaking news from Adjuvant Setting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr Vidula and Dr Langer review the role of oral selective estrogen receptor degraders (SERDs) in the treatment of ER+/HER2- metastatic breast cancer and what patient populations would benefit the most from treatment with oral SERDs.
A new study found that a deep-learning AI model predicted the risk for distant recurrence among patients with endometrial cancer.
The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.
The findings support the use of peritumoral lidocaine as a low-cost intervention prior to surgery for patients with early-stage breast cancer.
Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.